Biotechnology company CardiAI has announced the worldwide introduction and distribution of BPAro, a new 24-hour Ambulatory Blood Pressure Monitoring (ABPM) system.
The compact, portable, self-monitoring blood pressure device includes Bluetooth for the wireless collection of data, which is uploaded to a secure cloud database.
It is clinically validated for accuracy and has already received approvals from the US Food and Drug Administration (FDA) and Health Canada.
The German-manufactured device can serve as a diagnostic foundation by constantly monitoring human blood pressure and automatically recording patient blood pressure at regular intervals for up to 30 hours.
It has been designed and tested to be user-friendly and has simple instructions for patients and doctors.
The new ABPM device can collect blood pressure measurements at 30-minute intervals for up to seven days.
CardiAI founder and CEO Dr Anmol Kapoor said: “BPAro is the first to release among a number of point-of-care devices that will bridge the gap between a patient’s everyday life and the doctor’s office to aid in better patient treatment and preventative healthcare solutions.”
“High blood pressure can be a serious condition that could lead to heart attacks, strokes, kidney failure and loss of vision.
“Accurate and long-term blood pressure metrics aid in patient diagnosis and treatment. BPAro removes uncertainty and puts precision medicine in your hands.”
The device wirelessly uploads data to the BPAro app, and the data generated is used to create a blood pressure profile for each patient in a personal cloud account.
By synchronising the patient and physician results in real-time, the device provides blood pressure monitoring for evidence-based healthcare records.